Sandoz updates biosimilar development pipeline

May 7, 2014 9:31 AM

Following the Novartis Q1 announcements, Sandoz announced important updates on their biosimilar development programs.

The Swiss company continues to advance its biosimilars pipeline that currently has six molecules in the Phase III clinical trial/filing prep phase:

  • Sandoz completed the patient enrollment for its Phase III trial with biosimilar etanercept (Amgen’s Enbrel). The global clinical trial seeks to confirm biosimilarity with regard to safety, efficacy and immunogenicity of the Sandoz product versus Enbrel in patients with moderate to severe chronic plaque-type psoriasis.
  • Sandoz also completed a Phase III trial for the US registration of biosimilar filgrastim (Amgen’s Neupogen)and two global Phase III trials for global registration of biosimilar pegfilgrastim (Amgen’s Neulasta). The trials aimed to confirm biosimilarity of the Sandoz biosimilars versus Neupogen and Neulasta in breast cancer patients eligible for myelosuppresive chemotherapy treatment. Sandoz is currently preparing to file Filgrastim in the US and pegfilgrastim in the US and EU.

Sandoz also states that it is making strong progress on its other biosimilar clinical development programs which includes biosimilar versions of rituximab (Roche’s Rituxan/MabThera) and adalimumab (AbbVie’s Humira).

Sandoz currently markets three biosimilar products, each of which are #1 in their respective categories globally and has over 50 percent market segment share of all biosimilars approved in the highly regulated markets of U.S., Canada, Europe, Japan and Australia. Sandoz’ biosimilars are collectively sold in over 60 countries and have generated over 200 million patient exposure days of experience.


Source: Sandoz press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!